Summit Lens – Détails, épisodes et analyse

Détails du podcast

Informations techniques et générales issues du flux RSS du podcast.

Summit Lens

Eva

Sciences

Fréquence : 1 épisode/16j. Total Éps: 12

Healthcare is shaped by three forces: patients, policy, and products. Summit Lens explores what happens when science meets the real world — when a discovery becomes a drug, a drug meets the healthcare system, and new technologies change how medicine is developed and delivered. Each episode starts with one question and follows it through the system, so you come away understanding how healthcare works, why it matters, and what to watch next. Hosted by Shanyue.

Lire plusRéduire

Site

RSS

Apple

Données mises à jour le 17/09/2026

Classements récents

Dernières positions dans les classements Apple Podcasts et Spotify.

Apple Podcasts

Spotify

Aucun classement récent disponible

Liens partagés entre épisodes et podcasts

Liens présents dans les descriptions d'épisodes et autres podcasts les utilisant également.

Aucun lien partagé par ce podcast

Qualité et score du flux RSS

Évaluation technique de la qualité et de la structure du flux RSS.

Qualité du flux RSS

À améliorer

Score global : 58%

Historique des publications

Répartition mensuelle des publications d'épisodes au fil des années.

Year

Derniers épisodes publiés

Liste des épisodes récents, avec titres, durées et descriptions.

When AI Enters the Exam Room

Saison 1 · Épisode 12

dimanche 13 septembre 2026 • Durée 38:21

AI can already read scans, flag high-risk patients, guide ultrasound exams, and even make some autonomous diagnostic decisions.

But that raises a more important question: does a better model actually lead to better care?

In this episode, we follow what happens after the algorithm gives an answer. We look at why GPT-4 did not automatically make physicians better diagnosticians, how AI cut mammography reading workload by 44%, why some clinical alerts become noise while others speed up stroke treatment, and what happens when AI moves expertise closer to the patient.

We also look at one of the rare randomized trials linking an AI alert to lower mortality—and why some of the fastest-moving healthcare AI may be doing something far less glamorous: writing the clinical note.

The real story of medical AI may not be whether machines can outperform doctors. It may be whether healthcare systems know what to do with what the machines find.

Timestamps

00:08 The rise of AI in medicine
05:33 When smart AI doesn’t automatically make a smarter team
09:14 When the workflow is designed around AI
13:31 When an alert becomes noise
19:25 When the signal reaches an outcome
22:33 Moving expertise closer to the patient
28:21 Why the “boring” AI may move faster
31:24 Who decides when AI is good enough for healthcare?

Lire plusRéduire

When Healthcare Becomes an Investment Thesis

Saison 1 · Épisode 11

lundi 7 septembre 2026 • Durée 51:02

You may know your doctor.

But do you know who owns the business around your doctor?

Private equity usually does not show up in healthcare with a Wall Street label. It shows up more quietly, in the local practice that keeps its old name, the specialist group inside a hospital, or the clinic that suddenly feels more optimized than before.

The care may look familiar. The ownership may not be.

In this episode, we follow how private equity became one of the most important and least visible ownership forces in the US healthcare.

The story starts with the private equity model itself: raise capital, use leverage, buy a platform, add smaller practices, centralize operations, optimize revenue, and sell on a fund timeline.

Then we ask why healthcare fit that model so well.

The answer is uncomfortable: fragmented providers, opaque prices, third-party payment, complex billing, recurring demand, and physicians exhausted by the business side of medicine.

We follow that playbook from physician practices to emergency staffing, outpatient specialties, nursing homes, and hospital real estate.

This is not a simple story about private equity being good or bad.

Some practices need capital. Some physicians sell for rational reasons. Some platforms bring better technology and cleaner operations.

But when care becomes an investment asset, the logic around the exam room can change: what gets scheduled, what gets billed, which services grow, how doctors practice, and what patients experience without ever seeing the ownership change.

The takeaway is simple:

In the US healthcare, ownership is now part of the care model.

The question is no longer only, “Who is my doctor?”

It is also, “Who owns the system around my doctor and what is that owner optimized to do?”

Timestamps

00:07 When Healthcare Becomes an Investment Thesis
04:03 How the Private Equity Model Works
08:46 Why Healthcare Fit the Financial Engine
10:29 The Roll-Up Playbook
16:38 Envision, Surprise Billing, and the No Surprises Act
26:43 Specialty Roll-Ups and Outpatient Care

Lire plusRéduire

Why Hospitals Became the Price Setters

Saison 1 · Épisode 10

dimanche 30 août 2026 • Durée 56:10

Why can the same care cost more when the doctor, the room, and the service have not changed?

In this episode, we look at how hospitals became some of the most powerful price setters in American healthcare.

We start with a routine cardiology visit that suddenly costs almost three times more after the practice becomes part of a hospital system. From there, we unpack the larger structure behind that bill: hospital consolidation, must-have health systems, commercial prices, facility fees, physician practice acquisitions, and the policy fight over site-neutral payments.

This is not a simple story about hospitals being good or bad. Some health systems have enormous leverage. Some rural hospitals are barely staying open. And many policy solutions come with real tradeoffs.

But the central tension is clear: in healthcare, scale can create survival — and scale can create pricing power.

Timestamps

00:06 Why Hospitals Became the Price Setters
05:34 Hospitals as the Load-Bearing Wall of Healthcare Spending
12:10 Three Consolidation Playbooks
15:42 When the Bargaining Table Tips
19:07 Commercial Prices and the Cross-Subsidy Debate
25:21 Facility Fees and the Site-of-Care Economy
30:14 The Site-Neutrality Fight
33:06 Physician Practice Acquisition and Referral Control
34:27 The Anticompetitive Mechanisms Behind Doctor Buyouts
37:01 The Invisibility Problem in Healthcare Acquisitions
40:50 The Rural Hospital Tradeoff
45:15 Four Ways the System Pushes Back
52:37 Why Hospital Market Power Matters

Lire plusRéduire

Why Having Insurance Still Feels Expensive

Saison 1 · Épisode 9

mercredi 19 août 2026 • Durée 59:07

What does it actually mean to have health insurance in America?

In this episode, we look at the Affordable Care Act not as a partisan debate, but as a systems story.

The ACA changed who could enter the insurance market. It made it harder for insurers to deny coverage because of pre-existing conditions, removed annual and lifetime limits, expanded Medicaid in many states, and created subsidized marketplaces for people outside employer coverage.

But it did not fully change what care costs once someone gets inside the system.

So the central question is not simply whether the ACA succeeded or failed. It is what kind of problem the law was built to solve, and what kind of problem it left behind.

We follow that question from a kitchen table during open enrollment to pre-ACA medical underwriting, marketplace plan design, narrow networks, underinsurance, Medicaid expansion, temporary subsidies, and the deeper cost structure underneath American healthcare.

Because having insurance is not always the same as being able to afford care.

Timestamps

00:05 Why Having Insurance Still Feels Expensive
05:47 Before the ACA: The Exclusion Problem
13:36 How the ACA Rebuilt Insurance
22:41 When Coverage Is Hard to Use
33:16 Why Premiums and Deductibles Keep Rising
38:42 The Medicaid Expansion Divide
44:15 Temporary Subsidies and the 2026 Shock
48:39 What the ACA Solved and What It Didn’t
54:40 The Core Tradeoff and What Comes Next

Lire plusRéduire

When Washington Becomes the Drug Price Negotiator

Saison 1 · Épisode 8

mardi 11 août 2026 • Durée 58:39

What happens when Medicare stops only paying for drugs and starts naming the price?

In this episode, we look at the Inflation Reduction Act and Medicare drug price negotiation, not as a policy explainer, but as a shift in power inside the U.S. drug market.

For nearly two decades, Medicare Part D relied on private plans, PBMs, formularies, and rebates to negotiate drug costs. The IRA changed that architecture. Washington is now setting prices for selected high-spend Medicare drugs, and every part of the system is adapting around that new signal.

We follow the story from the pharmacy counter to the manufacturer revenue model, the Part D plan bid, the PBM rebate negotiation, and the biotech investment decision.

The question is no longer only whether Medicare can negotiate a lower price. It is what happens when that price becomes part of the operating system for the US drug markets.

Timestamps

00:10 Drug Pricing and the IRA
05:15 Medicare’s Old Bargain
10:05 How Washington Names a Price
13:46 Which Drugs Got Picked and Why
27:54 The Hidden Half: Part D Redesign
37:33 Pharma’s Strategic Response
46:32 PBMs Adapt, Not Disappear
51:00 What Patients Actually Experience
56:55 The New Price Signal

Lire plusRéduire

When GLP-1 Meets the Real World

Saison 1 · Épisode 7

lundi 15 juin 2026 • Durée 39:59

GLP-1 proved the science could work. The harder test began once patients tried to get it.

In this episode, we follow GLP-1 from the pharmacy counter into the real world of American healthcare: insurance coverage, compounding pharmacies, PBM formulary decisions, employer benefit design, cash pay pathways, TrumpRx, and public policy.

The question is no longer only whether these drugs work. It is how the system decides who gets access when a treatment is effective, expensive, highly demanded, and potentially preventive.

And for many patients, the answer depends on which door is actually open.

Timestamps

00:06 When the Prescription Isn’t Enough
07:47 How Compounding Became the Workaround
10:58 Why Coverage Still Creates Friction
16:17 Public Coverage and International Contrasts
21:53 PBMs, Employers, and the Formulary Fight
28:56 Cash Pay, TrumpRx, and New Access Lanes
35:19 The Pipeline Keeps Moving
35:48 Who Pays for Prevention?

Lire plusRéduire

How GLP-1 Went From Biology to Blockbuster

Saison 1 · Épisode 6

jeudi 4 juin 2026 • Durée 51:09

How did a gut hormone that disappeared in seconds become one of the biggest drug classes in the world?

In this episode, I walk through the story of GLP-1, from early scientific discovery and the Gila monster breakthrough to Novo Nordisk’s drug design strategy, Eli Lilly’s competitive push, and the shift that turned GLP-1 from a diabetes treatment into something much bigger.

This is a story about how a hard biological problem became a pharmaceutical platform, and how that platform began to change the way medicine thinks about obesity, metabolism, and chronic disease.

Timestamps

00:08 Intro: The 90-Second Hormone
02:23 The Gut’s Hidden Signal
05:01 The Discovery of GLP-1
10:32 The Gila Monster Breakthrough
16:04 Novo Solves the Delivery Problem
19:43 How GLP-1 Became a Platform
25:46 Beyond Diabetes
30:28 Lilly Raises the Benchmark
32:43 The Broader Implications of GLP-1
43:22 The future of GLP-1
49:14 When the Science Meets the System

Lire plusRéduire

Why Making the Drug Is Only Half the Battle

Saison 1 · Épisode 5

lundi 11 mai 2026 • Durée 55:08

What does it actually take to turn a scientific breakthrough into a drug patients can access?

In this episode, I look at the manufacturer side of the healthcare system, the part that absorbs scientific failure, funds long-shot bets, and then enters a second battle after the science succeeds. Because FDA approval is not the finish line. It is the point where a therapy enters the real commercial system: one shaped by patent clocks, launch pricing, payer resistance, formulary access, rebates, and budget pressure.

This is a story about the economics of failure, the logic of blockbuster drugs, and the central tension at the heart of modern pharma: scientifically essential, politically unpopular, financially powerful, and commercially constrained at the same time.

Between the lab bench and the patient sits a market that does not simply reward innovation. It prices it, filters it, delays it, and redistributes its value.

Timestamps

00:00 Intro: The Drug Exists. Access Still Breaks Down
05:44 FDA Approval Is Not the Finish Line
09:41 Inside the R&D Risk Machine
13:24 Why Most Drug Trials Fail
15:32 The Patent Clock Starts Early
24:39 Why U.S. Drug Prices Run Higher
29:19 The Gross-to-Net Bubble
40:16 The Pharma Paradox
44:05 The IRA Changes the Game
50:59 Invention Is Not Enough

Lire plusRéduire

Who Really Controls Your Prescription?

Saison 1 · Épisode 4

lundi 27 avril 2026 • Durée 01:08:39

If your doctor writes a prescription, who actually decides whether you get it, where you fill it, and what you pay?

In this episode, I unpack the hidden role of pharmacy benefit managers, or PBMs, the intermediaries that sit between drugmakers, insurers, employers, pharmacies, and patients. PBMs do not invent drugs or prescribe them, but they often control formularies, prior authorization, specialty pharmacy channels, and the financial terms that shape access.

I trace how PBMs evolved from claims processors into powerful gatekeepers, explain how rebates, spread pricing, specialty pharmacy, and step therapy work, and examine the central debate: are PBMs lowering costs, or making the system more opaque while controlling who gets what medicine?

From insulin and biosimilars to specialty drug markups and the latest reform pressure, this is a story about the financial architecture between the prescription pad and the patient.

Timestamps

00:00 — Cold open
03:23 — The pharmacy counter mystery
12:28 — Meet the PBM
16:35 — The evolution of PBMs
22:25 — How the machine works
38:01 — Why PBMs grew so powerful
49:33 — Critics vs. Defense
57:01 — What this means

Lire plusRéduire

How Private Insurers Took Over American Healthcare

Saison 1 · Épisode 3

mercredi 15 avril 2026 • Durée 53:39

What happens when an insurance company stops acting like a payer and starts acting like infrastructure?

In this episode, I explore how private insurers became some of the most powerful actors in American healthcare. Using UnitedHealth Group as a central case study, I trace the shift from passive bill payer to managed care gatekeeper to vertically integrated healthcare empire. From Medicare Advantage and self-funded employer plans to Optum, PBMs, and the Change Healthcare crisis, this is a story about how private insurers scaled, consolidated, and embedded themselves into the plumbing of the U.S. health system.

Timestamps

00:10 The role of health insurance in healthcare
07:02 The shift to managed care
11:00 Understanding UnitedHealth Group’s strategy
22:55 The impact of Medicare Advantage
33:25 Self-funded plans and pharmacy benefit managers
44:28 The vulnerability of consolidation
50:45 The corporate takeover of healthcare

Lire plusRéduire

Podcasts Similaires Basées sur le Contenu

Découvrez des podcasts liées à Summit Lens. Explorez des podcasts avec des thèmes, sujets, et formats similaires. Ces similarités sont calculées grâce à des données tangibles, pas d'extrapolations !

Il n'y a pas de contenu associé à ce podcast.

À propos Méthodologie Contact Me soutenir Politique de confidentialité Mentions légales

Summit Lens – Détails, épisodes et analyse

Détails du podcast

Classements récents

Apple Podcasts

Spotify

Liens partagés entre épisodes et podcasts

Qualité et score du flux RSS

Historique des publications

Derniers épisodes publiés

Podcasts et contenus similaires

Podcasts Similaires Basées sur le Contenu

Apple Podcasts

Spotify

Podcasts Similaires Basées sur le Contenu